康方生物“仅供临床研究使用”抗肿瘤药品流向患者，这一事件引发关注。康方生物方面称，该公司重庆销售人员通过伪造研究立项文件及医院伦理批件等材料，以研究者发起的药品上市后临床研究的名义，从公司骗取了若干药物。康方目前配合相关监督管理部门就此事件开展调查。这起事件牵涉康方、医药代表、医院、医生及患者各方，进一步的责任认定仍待监管机构给出。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.